



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



**Date: July 27, 2019**

<b>To</b> <b>The Department of Corporate Services</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 <b>Security Code: 540596</b>	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 <b>Symbol: ERIS</b>
---	--

**SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e. JULY 27, 2019**

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. July 27, 2019 duly approved and took on record the limited reviewed Unaudited Standalone Financial Results and the limited reviewed Unaudited Consolidated Financial Results for the quarter ended June 30, 2019.

Please find enclosed Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2019 along with the Limited Review Reports of the Auditors.

Further the Board of Directors of the Company decided to convene the thirteenth Annual General Meeting of the Company on Friday, 27<sup>th</sup> September, 2019.

The meeting of the Board of Directors commenced at 12:00 noon and concluded at 2:05 pm.

This is for your information and record.

Thanking You.

**For Eris Lifesciences Limited**

**Milind Talegaonkar**  
**Company Secretary & Compliance Officer**

**Encl: a/a**

**Registered & Corporate Office:**

8<sup>th</sup> Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in


CIN: L24232GJ2007PLC049867



**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019**

Particulars	[Rs. in Million except per share data]			
	For Quarter Ended			For Year Ended
	June 30, 2019 (unaudited)	March 31, 2019 (refer note 3)	June 30, 2018 (unaudited)	March 31, 2019 (Audited)
<b>Revenue from Operations</b>				
Sale of products	2,597.78	1,946.12	2,226.81	8,811.28
Other operating income	25.48	38.18	38.14	154.11
<b>Total Revenue from Operations</b>	<b>2,623.26</b>	<b>1,984.30</b>	<b>2,264.95</b>	<b>8,965.39</b>
Other Income	27.16	116.00	45.06	324.99
<b>Total Income</b>	<b>2,650.42</b>	<b>2,100.30</b>	<b>2,310.01</b>	<b>9,290.38</b>
<b>Expenses</b>				
Cost of materials consumed	155.38	115.44	134.14	581.88
Purchase of stock-in-trade	216.45	294.78	121.57	875.61
Changes in inventories of finished goods, work-in-progress and stock-in-trade	80.77	(106.75)	74.32	(133.99)
Employee benefits expense	447.76	410.38	434.82	1,667.66
Finance Costs	8.52	43.83	70.76	227.93
Depreciation and amortisation expense	101.86	100.35	60.86	315.89
Other expenses	719.25	651.25	659.36	2,637.64
<b>Total Expenses</b>	<b>1,729.99</b>	<b>1,509.28</b>	<b>1,555.83</b>	<b>6,172.62</b>
<b>Profit before Tax</b>	<b>920.43</b>	<b>591.02</b>	<b>754.18</b>	<b>3,117.76</b>
<b>Tax Expense</b>				
Current Tax	200.91	132.17	166.21	688.67
Deferred Tax	(100.06)	(65.31)	(113.07)	(424.72)
<b>Total Tax Expense</b>	<b>100.85</b>	<b>66.86</b>	<b>53.14</b>	<b>263.95</b>
<b>Net Profit for the period / year</b>	<b>819.58</b>	<b>524.16</b>	<b>701.04</b>	<b>2,853.81</b>
<b>Other Comprehensive Income</b>	<b>(3.73)</b>	<b>(1.98)</b>	<b>(0.33)</b>	<b>(0.99)</b>
Items that will not be reclassified to profit or loss	(5.74)	(3.05)	(0.50)	(1.52)
Income tax relating to items that will not be reclassified to profit or loss	2.01	1.07	0.17	0.53
<b>Total Comprehensive Income</b>	<b>815.85</b>	<b>522.18</b>	<b>700.71</b>	<b>2,852.82</b>
Paid Up Equity Share Capital (Face Value of Re.1 each)	137.52	137.52	137.51	137.52
Other Equity				11,422.55
<b>Earnings Per Share (of Re. 1 each) (not annualised) :</b>				
Basic	5.96	3.81	5.10	20.75
Diluted	5.95	3.81	5.09	20.74

See accompanying notes to the financial results



**Registered & Corporate Office:**

8<sup>th</sup> Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India  
 Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 / 71841000  
 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

1. The above statement of financial results ("the Statement") of the Company were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on July 27, 2019. The Statutory Auditors of the Company have carried out Limited Review of the Statement.
2. The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
3. The figures for the quarter ended March 31, 2019 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year.
4. The Company on November 06, 2018 has acquired 6.71% shareholding of Kinedex Healthcare Private Limited for a consideration of ₹ 107.21 million. The Company has acquired remaining 17.81% shareholding on April 06, 2019 for a consideration of ₹ 213.73 million in Kinedex Healthcare Private Limited making it a wholly owned subsidiary.
5. Effective from April 01, 2019, the Company has adopted Ind AS 116 "Leases" and applied it to all lease contracts existing on April 01, 2019 using modified retrospective method. Accordingly, comparatives for previous period / year have not been retrospectively adjusted. The adoption of standard has resulted in increase in depreciation and amortisation expense by ₹ 33.44 million, increase in finance costs on lease liability by ₹ 4.00 million, decrease in lease rent cost by ₹ 24.09 million and reduction in Profit after tax by ₹ 8.68 million.
6. Figures for the previous periods have been regrouped wherever considered necessary.



Place: Ahmedabad  
Date: July 27, 2019

For Eris Lifesciences Limited,



Amit Bakshi  
Chairman and Managing Director  
DIN : 01250925









